Evidence map›Paper›PMID 39001476›Full record

ArticleCancers2024

Incident Cancer Risk of Patients with Prevalent Type 2 Diabetes Mellitus in Hungary (Part 2).

Zsolt Abonyi-Tóth, György Rokszin, Gábor Sütő, Ibolya Fábián, Zoltán Kiss, György Jermendy, Péter Kempler, Csaba Lengyel, István Wittmann, Gergő A Molnár

Abstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zsolt Abonyi-TóthRxTarget Ltd., 5000 Szolnok, Hungary.ORCID 0000-0002-5585-3313
György RokszinRxTarget Ltd., 5000 Szolnok, Hungary.ORCID 0009-0002-0568-001X
Gábor SütőSecond Department of Medicine and Nephrology-Diabetes Centre, University of Pécs Medical School, 7624 Pécs, Hungary.
Ibolya FábiánRxTarget Ltd., 5000 Szolnok, Hungary.
Zoltán KissSecond Department of Medicine and Nephrology-Diabetes Centre, University of Pécs Medical School, 7624 Pécs, Hungary.
György JermendyDepartment of Internal Medicine, Bajcsy-Zsilinszky Hospital, 1106 Budapest, Hungary.ORCID 0000-0001-5596-7831
Péter KemplerDepartment of Medicine and Oncology, Faculty of Medicine, Semmelweis University, 1089 Budapest, Hungary.
Csaba LengyelDepartment of Internal Medicine, University of Szeged, 6720 Szeged, Hungary.
István WittmannSecond Department of Medicine and Nephrology-Diabetes Centre, University of Pécs Medical School, 7624 Pécs, Hungary.ORCID 0000-0001-5163-5733
Gergő A MolnárSecond Department of Medicine and Nephrology-Diabetes Centre, University of Pécs Medical School, 7624 Pécs, Hungary.ORCID 0000-0001-6052-5907

Funding

Hungarian Society of Diabetes n.a.
6 · The paper itself

Abstract

(1) Background: Among the chronic complications of type 2 diabetes mellitus, cancer has become the leading cause of death in several countries. Our objective was to determine whether prevalent type 2 diabetes mellitus is associated with a higher incidence of cancer. (2) Methods: This study comprised a nationwide analysis conducted in Hungary. The study population was divided into two groups: a type 2 diabetes mellitus group vs. a non-diabetic group. The primary outcome was the risk related to overall cancer incidence; a key secondary outcome was the overall incidence of cancer in distinct study years; and a further outcome was the annual percent changes. (3) Results: The odds ratio related to the overall incidence of cancer was 2.50 (95% confidence interval: 2.46-2.55,

Indexed as

agecancerdiabetes mellitus (type 2)epidemiologyincidence

Identifiers

PMID39001476
PMCPMC11240453

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.